コンドウ　ツネノリ   Kondou Tsunenori   近藤　恒徳    所属   医学部 医学科（附属足立医療センター）    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
掲載誌名	正式名：Clinical genitourinary cancer 略　 称：Clin Genitourin Cancer ISSNコード：19380682/15587673
掲載区分	国外
巻・号・頁	17(4),pp.e772-e778
著者・共著者	TACHIBANA Hidekazu, KONDO Tsunenori, TAKAGI Toshio, TANABE Kazunari, ISHIHARA Hiroki
担当区分	2nd著者
発行年月	2019/08
概要	INTRODUCTION:There is scarce information regarding nivolumab treatment for metastatic renal cell carcinoma (mRCC) in patients with end-stage renal disease (ESRD). This study investigated the safety and efficacy of nivolumab in patients with mRCC and ESRD.MATERIALS AND METHODS:This 2-center retrospective study evaluated 62 patients who were administered nivolumab for mRCC between June 2013 and August 2018. The ESRD group (n = 7) and non-ESRD group (n = 55) were compared in terms of their immune-related adverse events (irAEs), objective response rate, progression-free survival, and overall survival.RESULTS:All 7 patients with ESRD were male (median age, 67 years; range, 52-73 years), and their median duration of nivolumab use was 6.0 months (range, 1.8-8.2 months). One patient experienced a partial response, and 4 patients had stable disease. The objective response rate was lower in the ESRD group than in the non-ESRD group (16.7% vs. 37.5%; P = .25). Relative to the non-ESRD group, the ESRD group had slightly lower rates of all irAEs (42.9% vs. 58.7%) and grade 3 or higher irAEs (14.3% vs. 21.7%). The irAEs in the ESRD group were skin rash (grade 1), diarrhea (grade 1), and severe fatigue (grade 3) after the first nivolumab infusion, which required treatment discontinuation. The Kapan-Meier curves revealed no significant differences between the ESRD and non-ESRD groups in terms of progression-free (P = .63) and overall survival (P = .62).CONCLUSION:It may be possible to safely and effectively use nivolumab for select patients with mRCC and ESRD.
DOI	10.1016/j.clgc.2019.04.004
PMID	31101580